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3 Abstract 
4 
5 
6 Objectives: To assess the risk of significant adverse events in premature infants receiving the novel 
7 
8 group B meningococcal vaccine (4CMenB) with their routine immunisations at 2 months of age 
9 
10 Participants, design and setting: In December 2015, Public Health England requested neonatal units 
11 
12 across England to voluntarily participate in a national audit; 19 units agreed to participate. 
13 
14 Anonymised questionnaires were completed for infants receiving 4CMenB alongside their routine 
15 
16 immunisations. For comparison, a historical cohort of premature infants receiving their primary 
17 
18 immunisations without 4CMenB or paracetamol prophylaxis was used. 
19 
20 Main Outcome Measures: Paracetamol use; temperature, cardiovascular, respiratory and 
21 
22 neurological status before and after vaccination; management and investigations post-vaccination, 
23 
24 
including serum C-reactive protein levels, infection screens and antibiotic use. 
26 
27 Results: Complete questionnaires were returned for 133 premature infants (<35 weeks gestation) 
28 
29 who received their first dose of 4CMenB at 8 weeks of age, including 108 who received prophylactic 
30 
31 paracetamol according to national recommendations. Overall, 7% (8/108) of infants receiving 
32 
33 4CMenB with paracetamol had fever (>38°C) after vaccination compared with 20% (5/25) of those 
34 
35 receiving 4CMenB without paracetamol (p=0.06) and none of those in the historical cohort. There 
36 
37 were no significant differences between cohorts in the proportion of infants with apnoea, 
38 
39 
bradycardia, desaturation and receiving respiratory support after vaccination. 
40 
41 
Conclusions: 4CMenB does not increase the risk of serious adverse events in hospitalised premature 
43 
44 infants. This audit supports the current national recommendations to offer 4CMenB with other 
45 
46 routine vaccinations and prophylactic paracetamol to premature infants at their chronological age. 
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1 
2 
3 INTRODUCTION 
4 
5 In the UK, the novel, multi-component, protein-based vaccine against group B invasive 
6 
7 meningococcus disease (4CMenB, Bexsero, GSK, Rixensart) was introduced into the national infant 
8 
9 immunisation schedule in September 2015.[1] Infants are offered the vaccine at 2 and 4 months of 
10 
11 age, with a booster dose at 12 months. The vaccine was quickly shown to be highly effective against 
12 
13 meningococcal B (MenB) disease, with a nearly 50% reduction in cases among vaccine-eligible 
14 
15 
infants.[2] 
16 
17 
18 
19 
20 Initial pre-licensure clinical trials of 4CMenB in term infants identified high rates of fever in up to 
21 
22 60% of cases, as well as irritability, sleepiness and poor appetite, when administered alongside 
23 
24 routine infant immunisations.[3,4] Subsequently, a randomised controlled trial reported that 
25 
26 prophylactic paracetamol with the first dose, administered around the time of vaccination, reduced 
27 
28 the frequency of such adverse events to rates reported in infants receiving routine immunisations 
29 
30 without 4CMenB.[5] Moreover, prophylactic paracetamol did not have any adverse impact on the 
31 
32 immune response to any of the vaccine antigens. Consequently, prophylactic paracetamol at the 
33 
34 
time of vaccination with two further doses given 4-6 hours apart was recommended for all infants 
35 
36 
receiving 4CMenB along with their routine primary immunisations, including for preterm infants.[6] 
38 
39 There has, however, been a small increase in hospitalisations for fever following vaccination, 
40 
41 especially after the first dose.[7–10] 
42 
43 
44 
45 Premature infants are known to have a higher risk of serious bacterial infections compared to infants 
46 
47 born at term.[11] It is therefore critical that they are protected through timely vaccination. In the 
48 
49 UK, premature infants are recommended to receive their routine immunisations at their 
50 
51 chronological age, without any correction for prematurity.[12] There are, however, concerns that 
52 
53 premature infants – especially extremely premature infants and those with on-going health 
54 
55 
problems – may be at increased risk of adverse events following vaccination, particularly cardio- 
56 
57 
58 
59 
60  
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38 
1 
2 
3 respiratory instability and apnoea.[13] This had led some neonatal units (NNUs) to delay 
4 
5 immunisation with 4CMenB. Since cases of MenB disease increase from birth and peak by 5 months 
6 
7 of age, any delay in vaccination could leave the infant vulnerable to meningococcal disease, 
8 
9 especially because at least two priming doses of 4CMenB are required for adequate protection.[2] 
10 
11 
12 
13 
Data on the safety and immunogenicity of 4CMenB in premature infants are limited. Following a 
14 
15 
number of anecdotal reports of rapid deterioration following 4CMenB vaccination in some 
17 
18 premature infants, Public Health England (PHE) initiated a prospective national audit to assess the 
19 
20 outcomes of immunisation in premature infants receiving 4CMenB with their routine immunisations 
21 
22 in NNUs across England.[14] 
23 
24 
25 
26 
27 METHODS 
28 
29 Participants 
30 
31 In December 2015, the Immunisation Department at PHE, through the British Association for 
32 
33 Perinatal Medicine (BAPM), invited NNUs across England to voluntarily participate in a national audit 
34 
35 
to monitor the rate of adverse events in premature infants receiving 4CMenB concomitantly with 
36 
37 
their routine immunisations, 19 units agreed to participate. 
39 
40 
41 
42 Vaccination 
43 
44 Participating units immunised premature infants (gestational age <37 weeks at birth) as part of 
45 
46 routine clinical care. Immunisations took place between 04/10/2015 and 25/01/2017. The 
47 
48 administered vaccines included 4CMenB, 5-in-1 DTaP-IPV-Hib (diphtheria, tetanus, pertussis, 
49 
50 inactivated polio and Haemophilus influenzae type b [Hib]; Infanrix-IPV-Hib®, GSK or Pediacel®, 
51 
52 Sanofi Pasteur), the 13-valent pneumococcal conjugate vaccine (PCV13; Prevenar13®; Pfizer) and the 
53 
54 oral rotavirus vaccine (Rotarix®; GSK Biologicals, Rixensart). 
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1 
2 
3 Clinical Management of Infants 
4 
5 Any blood sampling, investigations or change in clinical management was conducted at the 
6 
7 discretion of the clinical team as part of clinical care. All samples were analysed at the infants’ local 
8 
9 hospital laboratory. 
10 
11 
12 
13 
Data collection 
14 
15 
An anonymised questionnaire was completed by the clinical team for all infants and included 
17 
18 gestational age, vaccination details and paracetamol use, temperature, cardiovascular, respiratory 
19 
20 and neurological status prior to and for 48 hours after vaccination, changes in clinical management, 
21 
22 results of any blood tests or microbiological investigations performed, and use of antibiotics after 
23 
24 vaccination. This evaluation was conducted to audit a nationally recommended intervention and 
25 
26 thus met NRES criteria for a service evaluation. Formal ethics review was, therefore, not required. 
27 
28 All information collected was anonymised at source. 
29 
30 
31 
32 Comparator Group 
33 
34 
For comparison, adverse reactions after vaccine administration were compared with data from a 
35 
36 
37 
historical cohort of premature infants who had received their primary immunisations without 
38 
39 4CMenB in similar NNUs across England as part of a randomised controlled trial assessing different 
40 
41 pneumococcal vaccination schedules (PUNS).[14] In the PUNS study, infants were vaccinated by the 
42 
43 study team after obtaining written informed consent from parents. Infants received 5-in-1 DTaP- 
44 
45 IPV-Hib (Pediacel®), meningococcal C conjugate vaccine (Menjugate®, Novartis, Siena) and PCV13. 
46 
47 Prophylactic paracetamol was not recommended but paracetamol could be administered post- 
48 
49 vaccination if required. 
50 
51 
52 
53 Data Management and Analysis 
54 
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1 
2 
3 Completed questionnaires were faxed or emailed securely to PHE at regular intervals. Data were 
4 
5 entered into a custom Microsoft Access Database and transferred to Stata version 13 (Stata Corp, 
6 
7 College Station, Texas) for analysis. For comparison with the PUNS cohort, only infants born before 
8 
9 35 weeks gestation were included in the analysis. An infant was considered to have received 
10 
11 prophylactic paracetamol if the first dose was administered within two hours of vaccination. Fever 
12 
13 
was defined as temperature greater than 38.0°C. 
14 
15 
16 
17 
18 
19 
20 appropriate. Statistical significance was defined as P<0.05. 
21 
22 
23 
RESULTS 
25 
26 Study population 
27 
28 Complete questionnaires were returned for 133 premature infants (<35 weeks gestation) receiving 
29 
30 their first dose of 4CMenB (4CMenB cohort). Their median gestational age at birth was 26.9 (IQR, 
31 
32 25.0-28.6) weeks and they were immunised at a median postnatal age of 63 (IQR, 59-74) days; 122 
33 
34 
(92%) received concomitant vaccinations (Table 1). The PUNS cohort (n=68) had a similar gestational 
35 
36 
37 age at birth (median 27.6 weeks, IQR 26.1-28.6) and postnatal age at vaccination (median 63 days, 
38 
39 IQR 57-68). All PUNS infants received concomitant vaccinations (Table 1). In the 48 hours prior to 
40 
41 vaccination, a similar proportion of infants in each cohort were receiving respiratory support (Table 
42 
43 1). 
44 
45 Most infants in the 4CMenB cohort received prophylactic paracetamol (n=108, 81%), with 91 infants 
46 
47 receiving all 3 paracetamol doses. None of the infants in the PUNS cohort had received prophylactic 
48 
49 paracetamol, and only five (9%) received paracetamol after vaccination for symptom management 
50 
51 (e.g. pain, unsettled). At the time of vaccination, infants receiving 4CMenB without paracetamol 
52 
53 
were older (median, 75 vs. 62 days, p<0.001) and more likely to have episodes of desaturation (60% 
54 
55 
56 
vs. 31%, p<0.001) compared with infants in the PUNS cohort. 
57 
58 
59 
60  
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Data that were not normally distributed are 
described as medians with interquartile ranges. Statistical comparisons were performed using the 
nonparametric Kruskal-Wallis one-way analysis of variance test, Χ2 test or Fisher’s exact test as 
 26 
1 
2 
3 
4 
5 Cardiorespiratory events and respiratory support after vaccination 
6 
7 There were no significant differences between the three cohorts in the proportion of infants with 
8 
9 apnoea, bradycardia, desaturation and receiving respiratory support after vaccination. Infants who 
10 
11 received 4CMenB without prophylactic paracetamol had a higher rate of desaturations before and 
12 
13 after vaccination compared with the other two groups (p=0.024) (Table 2). Infants born at less than 
14 
15 28 weeks gestation were more likely to have an increase in desaturations (43% versus 14%, p=0.002) 
16 
17 and bradycardias (35% versus 6%, p=0.001) compared with infants born after 28 weeks gestation. 
18 
19 These increased rates of desaturations and bradycardias after vaccination are similar in the historical 
20 
21 PUNS cohort. 
22 
23 
24 
25 
In the prophylactic paracetamol group, 11 infants (11%) had an increase in their ventilatory support 
27 
28 requirements, mainly infants who were spontaneously ventilating in air and required low-flow 
29 
30 oxygen support after vaccination (Supplementary table 1); one infant in this group had Gram- 
31 
32 negative sepsis and required intubation and ventilation. Among infants who did not receive 
33 
34 prophylactic paracetamol, three of ten on high-flow oxygen required increased respiratory support, 
35 
36 including one case each of continuous positive airway pressure ventilation (CPAP), biphasic positive 
37 
38 airway pressure ventilation (BIPAP) and intubation with invasive ventilation. In the PUNS cohort, 4 
39 
40 infants (6%) required escalation of ventilatory support to either high flow oxygen or CPAP, and 9% 
41 
42 self-ventilating infants had increased supplementary oxygen requirements after vaccination. 
43 
44 
45 
46 
47 
Fever after vaccination 
48 
Overall, 7% (8/108) of infants receiving 4CMenB with paracetamol had fever (38.0°C-39.0°C) after 
49 
50 vaccination compared with 20% (5/25) of those receiving 4CMenB without paracetamol (38.0°C- 
51 
52 38.7°C) (p=0.06) and none of those in the historical PUNS cohort (p=0.15 when comparing the 3 
53 
54 
groups). In the group receiving 4CMenB without prophylactic paracetamol, 5 out of 205 (2.4%) 
55 
56 
57 
58 
59 
60  
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 54 
1 
2 
3 temperature measurements taken within 48 hours of vaccination were >38.0°C compared with 7 out 
4 
5 of 906 measurements (0.8%) in those who received 4CMenB with paracetamol (p=0.037). 
6 
7 
8 
9 Sepsis assessment after vaccination 
10 Assessment for sepsis was not routinely reported for infants in the PUNS cohort. In the 4CMenB 
11 
12 cohort, 31 infants (25%) had screening bloods, 11 (9%) had a blood culture and 6 infants (5%) 
13 
14 
received empiric IV antibiotics during the first 48 hours after vaccination. A similar proportion of 
15 
16 
17 infants in the PUNS cohort (n=3, 4%) received IV antibiotics after vaccination. C-reactive protein 
18 
19 (CRP) results following vaccination are shown in Figure 1. Of the 17 infants in the 4CMenB cohort 
20 
21 who had a CRP level measured within 48 hours of vaccination, 13 (76%) had CRP levels >10 mg/dL, 4 
22 
23 (24%) >50 mg/dL and 1 (6%) >100 mg/dL. The median highest CRP following vaccination was 25.0 
24 
25 mg/dl (IQR 15.9-45.4). There was no difference in CRP levels between infants who received 4CMenB 
26 
27 with and without prophylactic paracetamol. 
28 
29 The only infant with CRP levels greater than 200mg/dL had Enterobacter cloacae bacteraemia, while 
30 
31 another infant with a peak CRP level of 73mg/dL had bacteraemia due to Pantoea sp. 
32 
33 
34 
35 DISCUSSION 
36 
37 
38 
39 4CMenB has the potential to significantly reduce the burden of invasive meningococcal disease in 
40 
41 infants and young children. The disease peaks at 5 months of age and, therefore, delays in 
42 
43 vaccination could potentially put the infants at increased risk. This is particularly the case for 
44 
45 premature infants who are known to be more susceptible to infection. 4CMenB is reactogenic, 
46 
47 especially when co-administered with the other routine infant immunisations, but clinical trials in 
48 
49 support the use of prophylactic paracetamol to reduce the rate of adverse events. The national 
50 
51 
decision to offer prophylactic paracetamol to all premature infants was divisive among 
52 
53 
neonatologists, with a number of units offering paracetamol only for treatment of vaccine-related 
55 
56 adverse events such as fever, either because they surmised that premature infants were less likely to 
57 
58 
59 
60  
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 1 
2 
3 mount a high pro-inflammatory response to vaccination or because of safety concerns regarding 
4 
5 unnecessary paracetamol use in this vulnerable age group. We found no evidence of any increase in 
6 
7 significant adverse events when premature infants are administered 4CMenB with their routine 
8 
9 vaccinations under prophylactic paracetamol cover. Our data also indicate that most premature 
10 
11 infants tolerated immunisation well and remained clinically stable during the period after 
12 
13 
vaccination. 
14 
15 
16 
17 
18 Although we used a historical cohort for comparison, all the infants were vaccinated under real-life 
19 
20 conditions with their on-going health problems in NNUs across England. The demographics of the 
21 
22 PUNS and 4CMenB cohorts prior to vaccination and their outcomes after immunisation were very 
23 
24 similar, thus providing reassurance that the risk of adverse events has not increased following the 
25 
26 introduction of 4CMenB into the routine immunisation schedule. We found that post-vaccination 
27 
28 fever was infrequent in all groups, especially when compared with pre-licensure clinical trials in term 
29 
30 infants with and without prophylactic paracetamol.[4,15,16] We also found some evidence of 
31 
32 infants receiving 4CMenB without prophylactic paracetamol having a higher risk of fever after 
33 
34 
vaccination. This observation would support the current national recommendation for prophylactic 
35 
36 
37 
paracetamol with 4CMenB for all infants.[6] 
38 
39 
40 
41 A significant concern among neonatologists was the potential for respiratory deterioration after 
42 
43 vaccination that might require escalation of ventilatory support. This, however, was uncommon, 
44 
45 with the majority of infants not requiring any additional support or only supplemental oxygen. In 
46 
47 particular, escalation to invasive ventilation after vaccination was uncommon in all cohorts. 
48 
49 
50 
51 There were also concerns that the use of very reactogenic vaccine may lead to a higher number of 
52 
53 infection screens being performed with increased consequent empiric antibiotic use. Whilst 
54 
55 
information on investigations performed was not systematically collected for the PUNS cohort, the 
56 
57 
58 
59 
60  
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 1 
2 
3 proportion of infants treated for suspected (culture-negative) sepsis was low in both groups. Of 
4 
5 note, most infants who had a blood test during the first 48 hours after receiving 4CMenB had raised 
6 
7 CRP levels, which is to be expected since the vaccine, in common with all vaccinations, aims to 
8 
9 trigger a pro-inflammatory response to induce immune protection. [17] This [the raised CRP levels] 
10 
11 needs to be taken into consideration when assessing infants who appear unwell after 4CMenB 
12 
13 
vaccination. 
14 
15 
16 
17 
18 Our data confirm that a small proportion of preterm infants, especially those born under 28 weeks 
19 
20 gestation, will deteriorate after vaccination, irrespective of whether they receive 4CMenB with or 
21 
22 without paracetamol prophylaxis. It is, therefore, reassuring that the infants are being closely 
23 
24 monitored in neonatal units and can, therefore, receive immediate care to manage any adverse 
25 
26 reaction. The approach by some NNUs to delay 4CMenB vaccination until the day of hospital 
27 
28 discharge or to request general practitioners to give the first vaccinations to the infant in the 
29 
30 community is, therefore, questionable, especially given the number of infant MenB cases that might 
31 
32 have been prevented through timely vaccination.[2] 
33 
34 
35 
36 
37 
Strengths and limitations 
38 
39 This multicentre audit exemplifies the willingness of NNUs across the country to work together to 
40 
41 provide near-real time data to support national policy. The lack of safety data in preterm infants for 
42 
43 such a novel vaccine had raised concerns among neonatologists, which was fuelled by anecdotal 
44 
45 reports of severe adverse events, mainly relating to escalation of ventilatory support and increased 
46 
47 screening for sepsis because of fever and associated symptoms after vaccination. This audit began 
48 
49 within a few weeks of the 4CMenB programme and near real-time monitoring of the completed 
50 
51 questionnaires provided on-going reassurance to support the current national recommendations to 
52 
53 vaccinate premature infants according to their chronological age. One limitation of this analysis was 
54 
55 
the inevitable use of a historical cohort because it would be unethical to have a contemporaneous 
56 
57 
58 
59 
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26 
1 
2 
3 comparator cohort without 4CMenB. As with any historical comparison, our analysis was limited to 
4 
5 the available data. The routine vaccines offered with alongside 4CMenB, for example were similar to 
6 
7 but not exactly the same as those used in the clinical trial. However, the overall risk of adverse 
8 
9 events after immunisation is likely to be more important for clinicians, rather than risks associated 
10 
11 with specific vaccines or vaccine combinations. Due to the nature of audits decisions relating to 
12 
13 
individual infants – such as fitness for vaccination, decisions to offer paracetamol prophylaxis, 
14 
15 
managing adverse events after vaccination, initiating sepsis screening and empiric antibiotics – were 
17 
18 not standardised as in a clinical trial, for example, but were at the discretion of the attending 
19 
20 clinician. The inclusion of so many NNUs in the audit should, however, provide a representative 
21 
22 overview of the current status across the country. 
23 
24 
25 
CONCLUSION 
27 
28 
29 When compared with previous vaccine schedules, the inclusion of 4CMenB is not associated with 
30 
31 any significant increase in severe adverse events among hospitalised premature infants. This audit 
32 
33 supports the current national recommendation to immunise premature infants at their chronological 
34 
35 age and to offer a routine three-dose prophylactic paracetamol course when 4CMenB is given 
36 
37 alongside the routine vaccinations. The Medicines and Healthcare products Regulatory Agency 
38 
39 (MHRA) continues to monitor the safety of all vaccines in the national immunisation programme; 
40 
41 any severe/unexpected adverse events should be reported to the MHRA. 
42 
43 
44 
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 Administration of 4CMenB did not increase desaturations, bradycardias and apnoeas in 
hospitalised preterm infants 
CRP level >10mg/dL was common after vaccination 
16 
1 
2 
3 What is already known on this topic: 
4 - Premature infants are at higher risk of many vaccine preventable diseases and timely 
5 
6 vaccination is critical. However, there are concerns about adverse events following vaccination 
7 
8 of premature infants. 
9 - 4CMenB (Bexsero) protects against invasive meningococcal disease but is associated with high 
10 
11 rates of post-vaccination fever and systemic side-effects. Paracetamol co-administration is 
12 recommended nationally. 
13 
14 - There are currently no published data on adverse events following 4CMenB vaccination in 
15 premature infants 
17 What this study adds: 
18 
-
 
19 
20 
21 
22 - We found some evidence of increased fever after vaccination in infants immunised with 
23 4CMenB without paracetamol prophylaxis 
24 
25 - 
26 
27 
28 
29 
30 
31 
32 
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34 
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 1 
2 
3 Tables 
4 
5 Table 1. Baseline characteristics of premature infants at the time of first vaccination in the PUNS 
6 cohort and the 4CMenB (Bexsero) cohorts with and without paracetamol. 
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26 
Median (IQR) or n(%). Respiratory support at the time of vaccination includes supplementary 
27 
28 
oxygen. Ventilated days: days of invasive ventilation only. Fever: Temperature ≥38°C. NA indicates 
29 
data not available. *p<0.05 
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 PUNS Bexsero Bexsero with 
paracetamol 
Bexsero without 
paracetamol 
N 68 133 108 25 
Gestation 27.6 (26.1-28.6) 26.9 (25.0-28.6) 26.9 (25.2-28.5) 26.9 (23.9-28.7) 
Ventilated 
days 
NA 7 (2-29) 5.5 (1-24) 30 (7-53)* 
Postnatal age 63 (57-68) 63 (59-74) 62 (59-71) 75 (64-102)* 
Concomitant 
vaccinations 
68 (100) 122 (92) 101 (94) 21 (84) 
Fever NA 3 (2) 3 (3) 0 (0) 
Apnoea 3 (4) 10 (8) 9 (8) 1 (4) 
Desaturations 28 (41) 48 (36) 33 (31) 15 (60)* 
Bradycardia 11 (16) 19 (14) 14 (13) 5 (20) 
Reduced 
consciousness 
NA 1 (1) 1 (1) 0 (0) 
Analgesia NA 9 (7) 9 (8) 0 (0) 
Respiratory 
Support 
40 (59) 98 (74) 78 (72) 20 (80) 
 
 Con 
1 
2 
3 Table 2: Adverse events in the 48 hours after immunisation among premature infants in the PUNS 
4 cohort and the 4CMenB (Bexsero) cohorts with and without paracetamol. 
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32 Respiratory support includes supplemental oxygen. Fever was defined as temperature ≥38°C. 
33 Improved, deteriorated and no change are compared with pre-vaccination status i.e. no change 
34 means the infants either had no symptoms prior to and in the 48 hours following vaccination, or 
35 they had symptoms but these were stable before and after the vaccination period. Data on reduced 
36 consciousness were not collected for the PUNS cohort. Due to missing data, percentages may not 
37 total to 100%. Median (IQR) or n (%). NA indicates data not available. *p<0.05 
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 PUNS Bexsero (all) Bexsero with 
paracetamol 
Bexsero without 
paracetamol 
N 68 122 108 25 
Fever 0 (0) 13 (10) 8 (7) 5 (20) 
Apnoea 11 (16) 19 (14) 18 (17) 1 (4) 
Improved 3 (4) 3 (2) 2 (2) 1 (4) 
Deteriorated 8 (12) 15 (11) 14 (13) 1 (4) 
No change 57 (84) 102 (77) 80 (74) 22 (88) 
Desaturations 26 (38) 72 (54) 53 (49) 19 (76)* 
Improved 9 (13) 12 (9) 8 (7) 4 (16) 
Deteriorated 18 (26) 43 (32) 33 (31) 10 (40) 
No change 39 (57) 52 (39) 45 (42) 7 (28) 
Bradycardia 15 (22) 44 (33) 36 (33) 8 (32) 
Improved 4 (6) 5 (4) 4 (4) 1 (4) 
Deteriorated 12 (18) 32 (24) 25 (23) 7 (28) 
No change 50 (74) 76 (57) 60 (56) 16 (64) 
Respiratory support 40 (59) 102 (77) 82 (76) 20 (80) 
Improved 2 (3) 5 (4) 6 (6) 0 (0) 
Deteriorated 4 (6) 14 (12) 11 (12) 3 (14) 
No change 62 (91) 102 (84) 82 (82) 19 (86) 
Reduced 
consciousness 
N/A 3 (3) 3 (2) 0 (0) 
Improved  0 (0) 0 (0) 0 (0) 
Deteriorated  3 (2) 3 (3) 0 (0) 
No change  110 (83) 88 (81) 22 (88) 
 
 Confidential
: 
For 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Distribution of CRP levels in preterm infants having a blood test after receiving 4CMenB with their 
routine immunisations in the neonatal unit. Dashed horizontal line marks the normal range upper limit 
(10mg/dL). Note the logarthmic Y axis. The two outlying results greater than 200 mg/dl dL are from an a 
single infant with Gram negative bacteraemia. 
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1 
2 
3 Supplementary data 
4 
5 Supplementary table 1: Change in ventilatory support in the 48 hours after vaccination in infants 
6 receiving 4CMenB with prophylactic paracetamol 
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18 
19 SVIA: Self-ventilating in air, CPAP: continuous positive airway pressure, BiPAP: Biphasic positive 
20 airway pressure, IPPV: Intermittent positive pressure ventilation. Respiratory support is the 
21 
22 maximum respiratory support given immediately prior to and within 48 hours after vaccination. 
23 Supplementary table 2: Change in ventilatory support in the 48 hours after vaccination in infants 24 
25 receiving 4CMenB without prophylactic paracetamol 
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SVIA: Self-ventilating in air, CPAP: continuous positive airway pressure, BiPAP: Biphasic positive 
38 airway pressure, IPPV: Intermittent positive pressure ventilation. Respiratory support is the 
39 maximum respiratory support given immediately prior to and within 48 hours after vaccination. 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60  
 After vaccination 
 
 
 
Before 
vaccination 
 SVIA Low flow O2 High flow O2 CPAP BiPAP IPPV 
SVIA 22 6 0 0 0 0 
Low flow O2 2 35 1 3 0 0 
High flow O2 0 2 20 0 0 1 
CPAP 0 0 0 5 0 0 
BiPAP 0 0 0 1 0 0 
IPPV 0 0 0 0 0 1 
 
 After vaccination 
 
 
 
Before 
vaccination 
 SVIA Low flow O2 High flow O2 CPAP BiPAP IPPV 
SVIA 5 0 0 0 0 0 
Low flow O2 0 4 0 0 0 0 
High flow O2 0 0 7 1 1 1 
CPAP 0 0 0 2 0 0 
BiPAP 0 0 0 0 1 0 
IPPV 0 0 0 0 0 0 
 
